HOME >> MEDICINE >> NEWS
Prescribing inconsistencies in prostate cancer treatment in the UK when using LHRHAs

London, 12 December 2006 -- Eighty-four percent of GPs and 76 percent of specialists (uro-oncologists or urologists) agree that there is a significant legal risk associated with off-label prescribing in prostate cancer when there is a licensed alternative available, according to new survey data released today.[1] Despite this, 46 percent of specialists felt that primary care commonly changes the recommended Leutinising Hormone-Replacement Hormone agonist (LHRHa) when referring management of patients to the community.

The Need for a Data Driven Solution

The data show that nearly all (92 percent) specialists, GPs, oncology pharmacists and specialist urology nurses surveyed agree that patients should receive an LHRHa with supporting clinical evidence wherever possible. Zoladex (goserelin) is licensed for all stages of prostate cancer suitable for hormonal manipulation.[2] Also, it is the only LHRHa with a proven survival benefit in adjuvant treatment in high risk localised disease and in adjuvant treatment of locally advanced prostate cancer when compared to surgery or radiotherapy alone.[3],[4],[5] However, when asked to differentiate between goserelin and another LHRHa not licensed for all stages of prostate cancer suitable for hormone manipulation, 75 percent of GPs and 42 percent of specialists felt in their view that the clinical evidence was the same.

Commenting on the data, Dr Heather Payne, Consultant Clinical Oncologist in Urological Tumours, University College Hospital, London stated: "Prostate cancer is a complicated disease and can be treated in several different ways. Depending on the stage of the cancer, a clear understanding of the supporting clinical evidence for treatments should guide prescribing decisions. As healthcare professionals, we need to provide patients with the best evidence-based treatment and care at all times."

Secondary and Primary Care Divide

Although 76 percent
'"/>

Contact: Marianne Thrall
mthrall@hillandknowlton.com
20-741-33733
Hill and Knowlton
12-Dec-2006


Page: 1 2 3

Related medicine news :

1. Prescribing information for kidney disease far too vague
2. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
3. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
4. African-American men understimate risk of prostate cancer
5. Treatment for early prostate cancer associated with type of specialist seen
6. Nonhormonal drug reduces hot flashes in men treated for prostate cancer
7. Flaxseed stunts the growth of prostate tumors
8. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
9. Radium-223: An alternative treatment for prostate cancer
10. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
11. New prostate cancer clinical guidelines to be released

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/11/2019)... , ... January 11, 2019 , ... In Partnership with ... dental services for low-income, underinsured individuals at its Burleson, TX office on ... and x-rays, fillings, cleanings and extractions . For more information, please ...
(Date:1/11/2019)... ... January 11, 2019 , ... ... radio station, WJR-760. , Dr. Jonathan Zaidan, President of Women’s Excellence, will co-host ... the third Wednesday of each month at 7pm. , "We are excited to ...
(Date:1/10/2019)... ... ... Tuesday, January 8, Dr. Samuel Joseph, Jr. , assisted by Dr. Andrew Moulton ... Systems revolutionary 3D Printed Aries Titanium Spinal Implant . “As a surgeon, it’s ... life so quickly,” commented Dr. Joseph, founder of Joseph Spine. “Today we were able to ...
(Date:1/10/2019)... , ... January 10, 2019 , ... ... introducing their Cellulose Tencel CBD Infused Face Mask. CBD, or Cannabidiol, is one ... properties research has shown that CBD influences receptors that are naturally present in ...
(Date:1/8/2019)... (PRWEB) , ... January 08, 2019 , ... ... East Point, Morrow, South DeKalb and West End communities have a new option ... to their network, effective immediately. , JenCare operates five centers in Atlanta ...
Breaking Medicine News(10 mins):
(Date:1/14/2019)... ... 14, 2019 , ... The Isagenix Legacy Foundation ... nonprofits that align with its mission to provide healthy nutrition and support for ... disasters. Located in Arizona, California, Georgia, Massachusetts, Maryland, Michigan, and Montana, the nonprofits ...
(Date:1/14/2019)... ... ... Sigma Theta Tau International Honor Society of Nursing (Sigma) was awarded two 2018 American ... one of the most important and prestigious designations of excellence in nursing book publishing. ... Sigma for the last 10 consecutive years. , Following are the Sigma books recognized ...
(Date:1/14/2019)... BOLOGNA, Italy (PRWEB) , ... January 13, 2019 , ... ... markets, is proud to announce the Memor™ 10 rugged mobile computer , one ... , MEMOR™ 10 is part of a new family of rugged Android PDA ...
Breaking Medicine Technology:
Cached News: